Navigation Links
FightSMA Awards $250,000 Grant to Gene Researcher at The Ohio State University
Date:5/19/2010

FightSMA, a nonprofit dedicated to developing a treatment for the deadly childhood crippler spinal muscular atrophy (SMA), is awarding a $250,000 research grant to Dr. Brian Kaspar, a principal investigator at Nationwide Children's Hospital and associate professor of The Ohio State University.

(PRWEB) May 19, 2010 -- Richmond, Virginia-based FightSMA, a nonprofit dedicated to developing a treatment for the deadly childhood crippler spinal muscular atrophy (SMA), is awarding a $250,000 research grant to Dr. Brian Kaspar, a principal investigator at Nationwide Children's Hospital and associate professor of The Ohio State University.

The grant will support safety and toxicity studies for AAV(-9), a potential “delivery system” for gene therapy for the treatment of SMA. "Our SMA gene therapy program at Nationwide Children's Hospital and The Ohio State University continues to show great promise for treating SMA patients," said Dr. Kaspar. "With this award, we will be able to test our therapy for potential safety or toxicity issues and provide important information for the regulatory process as we advance our program to the clinic in a swift and safe manner. We are all very thankful for the support of FightSMA."

The grant has been made possible by funding both from FightSMA (www.fightsma.org) and from its associated partner organization, The Gwendolyn Strong Foundation (www.gwendolynstrongfoundation.org). “We are tremendously excited about the potential for gene therapy in SMA and our continuing collaboration with The Gwendolyn Strong Foundation and the SMA Community,” said FightSMA President Martha Slay. “Gene therapy research is a marathon run, but the work of Dr. Kaspar will advance the field significantly for SMA.”

Spinal muscular atrophy (SMA) is the leading genetic cause of infant death. SMA is caused by the absence of a gene that is critical for muscle strength, the SMN (“survivor motor neuron”) gene. That gene is absent in approximately one in 30 individuals. If both a man and woman are lacking the necessary SMN gene, the chances are 25% that any of their children will manifest SMA.

An objective of gene therapy is the restoration of the missing gene through delivery systems called “vectors.” Adeno-associated virus (AAV) is considered to be an attractive candidate for the construction of vectors.

FightSMA was created in 1991 with the mission to “strategically accelerate the development of a treatment or a cure for spinal muscular atrophy.” Working with the guidance of an international Scientific Advisory Committee, FightSMA has awarded SMA research grants at more than 40 universities and research institutions in the United States, Canada, the United Kingdom, France, and Italy. FightSMA has chapters across the United States and in Canada.

For more information, contact: www.fightsma.org or 804.515.0080

# # #

Read the full story at http://www.prweb.com/releases/spinal-muscular-atrophy/research/prweb4022064.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Pennsylvania EPA Awards Abington Memorial Hospital Funding for Green Projects
2. Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinsons Disease Biomarker Pipeline
3. Estes Audiology Awards Hearing Aids to Two Worthy Recipients in Central Texas
4. Ascension Health Hospital Awards Streamline Health Contract to Ensure OSHA Compliance
5. Yalumba Accepts 'New World Winery Of The Year' Award At Wine Enthusiast Magazine 2009 Awards Gala
6. Ronald McDonald House Charities(R) (RMHC(R)) Awards Nearly $3 Million to Non-Profit Organizations
7. The Kenneth Rainin Foundation Awards $457,000 in Grants to Support Dance, Theater, Film and Early Literacy in the San Francisco Bay Area
8. National Center on Minority Health and Health Disparities awards $8 million to Weill Cornell
9. World Congress Announces Affordable Innovations in Health Exhibit and Awards 2010 at 7th Annual World Health Care Congress, Calls for Submissions from Organizations Striving to Improve Global Health Care
10. Childhood Apraxia of Speech Association of North America Awards Treatment Research Grant to University of New Mexico/PROMPT Institute
11. Three Pioneering Ideas in Cancer Research Granted Prestigious Damon Runyon-Rachleff Innovation Awards
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FightSMA Awards $250,000 Grant to Gene Researcher at The Ohio State University 
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology: